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Abstract
Background Despite increasing knowledge of the pathogenesis of muscle ageing, the molecular mechanisms are
poorly understood. Based on an expression analysis of muscle biopsies from older Caucasian men, we undertook an
in-depth analysis of the expression of the long non-coding RNA, H19, to identify molecular mechanisms that may con-
tribute to the loss of muscle mass with age.
Methods We carried out transcriptome analysis of vastus lateralis muscle biopsies from 40 healthy Caucasian men
aged 68–76 years from the Hertfordshire Sarcopenia Study (HSS) with respect to appendicular lean mass adjusted
for height (ALMi). Validation and replication was carried out using qRT-PCR in 130 independent male and female par-
ticipants aged 73–83 years recruited into an extension of the HSS (HSSe). DNA methylation was assessed using
pyrosequencing.
Results Lower ALMi was associated with higher muscle H19 expression (r2 = 0.177, P < 0.001). The microRNAs,miR-
675-5p/3p encoded by exon 1 of H19, were positively correlated with H19 expression (Pearson r = 0.192 and 0.182,
respectively, P < 0.03), and miR-675-5p expression negatively associated with ALMi (r2 = 0.629, P = 0.005). The
methylation of CpGs within the H19 imprinting control region (ICR) were negatively correlated with H19 expression
(Pearson r = 0.211 to 0.245, P ≤ 0.05). Moreover, RNA and protein levels of SMAD1 and 5, targets of miR-675-
3p, were negatively associated with miR-675-3p (r2 = 0.792 and 0.760, respectively) and miR-675-5p (r2 = 0.584
and 0.723, respectively) expression, and SMAD1 and 5 RNA levels positively associated with greater type II fibre size
(r2 = 0.184 and 0.246, respectively, P < 0.05).
Conclusions Increased expression profiles of H19/miR-675-5p/3p and lower expression of the anabolic SMAD1/5
effectors of bone morphogenetic protein (BMP) signalling are associated with low muscle mass in older individuals.
Keywords Muscle mass; Long non-coding RNA; SMAD
OR IG INAL ART ICLE
© 2021 The Authors. JCSM Rapid Communications published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
JCSM Rapid Communications 2021; 4: 207–221
Published online 15 June 2021 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/rco2.44
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
Received: 11 January 2021; Revised: 27 April 2021; Accepted: 12 May 2021
*Correspondence to: Karen Lillycrop, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK. Phone:
+442380593332, Fax: +442380595545, Email: kal@soton.ac.uk
†These authors are joint first authors.
‡These authors are joint senior authors.
Introduction
A decline in muscle mass and strength is a fundamental con-
sequence of ageing. Adequate skeletal muscle is essential for
all aspects of physical function, as well as for metabolism and
thermoregulation; consequently, the progressive loss of mus-
cle mass and strength with advancing age is associated with a
number of adverse physical and metabolic changes.1,2
The maintenance of muscle mass is controlled by multiple
interconnected signalling pathways, which regulate anabolic
and catabolic signals in the muscle and the balance between
muscle atrophy and hypertrophy.3 During ageing, this balance
is disrupted, with a decline in the production of anabolic hor-
mones and increased anabolic resistance,4 impaired protein
synthesis,5 denervation,6 loss of regenerative muscle satellite
cell activity,7,8 and reduced mitochondrial function, which re-
sults in decreased muscle mass and function.9,10 The expres-
sion and/or activity of many of the genes that regulate these
processes, or co-ordinate the integration of the signalling
pathways such as insulin-like growth factor 1,11 the androgen
receptor,12 50 adenosine monophosphate-activated protein
kinase,13 myostatin,14 Notch,15 WNT,16 Sirtuin 1,17 and Id
myogenic repressors,18 have also been reported to be altered
in ageing muscle. Consistent with these findings,
transcriptomic studies either using expression arrays or
RNAseq on muscle biopsies from young versus old individuals
have shown increased expression of pathways regulating cell
growth, complement activation, ribosomal and extracellular
matrix genes, as well as RNA binding/processing proteins,
and components of the ubiquitin-proteasome proteolytic
pathway in older muscle, while genes enriched in pathways
associated with chloride transport and mitochondrial oxida-
tive phosphorylation were down-regulated.19–21
However, there is significant variability between individ-
uals in the rate of loss of muscle mass in old age. Some of
the variability can be explained by fixed genetic factors,22,23
but much of the remaining variation is unexplained. To date,
most of the studies that have identified genes associated with
muscle ageing have compared changes in muscle tissue from
young versus old individuals, and the contribution that these
genes make to the variability observed between older indi-
viduals in terms of loss of muscle strength and mass is un-
known. To address this, we recently compared muscle
transcriptomic profiles from individuals with sarcopenia com-
pared with healthy aged matched controls from the
Singapore Sarcopenia Study and found that the major tran-
scriptional pathway associated with sarcopenia was mito-
chondrial dysfunction, with similar pathways altered with
respect to sarcopenia in the Hertfordshire Sarcopenia Study
(HSS) and the Jamaica Sarcopenia Study (JSS).21 To identify
the changes in transcription associated with the loss of mus-
cle mass, one of the definitional components of sarcopenia,
here, we report the transcriptomic analysis of skeletal muscle
biopsies from older individuals from the HSS with respect to
appendicular lean mass index (ALMi), together with an
in-depth analysis of the expression of the long non-coding
RNA, H19, the top transcript positively associated with ALMi
to identify molecular mechanisms that may contribute to
the loss of muscle mass with age.
Methods
Study participants
All participants were recruited from the UK Hertfordshire
Cohort Study (HCS).24 The HSS, a sub-study of the HCS, was
designed to investigate life course influences on muscle
morphology, mass, and strength in community-dwelling older
people. The first phase of the study has previously been
described in detail.25 The second, extension phase of the
study (HSSe) recruited a total of 168 men and women. The
skeletal muscle characterization carried out in this study in-
cluded total lean mass and body composition ascertained
by dual-energy X-ray absorptiometry (DXA) scanning, hand-
grip strength determined by using a Jamar hydraulic dyna-
mometer (Promedics, UK), and physical capability measured
by gait speed timed over 3 m.26 Percutaneous muscle biop-
sies of the vastus lateralis were conducted after an overnight
fast under local anaesthetic using a Weil-Blakesley
conchotome.27 A portion of muscle tissue was used for cell
culture while another portion was snap frozen in cooled
isopentane and stored at 80°C until further analysis.
Out of the 105 male participants recruited in the HSS, 40
were selected for RNAseq analysis; these were the only sam-
ples that had sufficient RNA for RNAseq analysis. Fifty-seven
HSS samples were analysed by qRT-PCR; this included 37 sam-
ples analysed by RNAseq (six had insufficient RNA remaining
after the RNAseq analysis) and 20 additional samples for which
there was sufficient RNA for qRT-PCR analysis. This approach
was taken to increase power for the qRT-PCR analysis. Follow-
ing QC of the qRT-PCR data, three of the 37 samples with
RNAseq data and two of the 20 additional samples failed QC
(melt curves showing primer dimers) and were excluded from
the analysis, leaving a total of 52 samples with qRT-PCR data
(34 with RNAseq data and 18 additional HSS samples).
To replicate the findings in an independent cohort and to
determine whether the association was observed in both
men and women, qRT-PCR was also carried out on 130 male
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and female participants from the HSSe; these were the only
participants with sufficient RNA. Myoblast cultures from a to-
tal of nine biopsies were used for transfection analysis to de-
termine the causal role for H19 in regulating human skeletal
muscle mass. A schematic for all the samples used in the
different analyses can be found in Supporting Information,
Figure S1. The study received ethical approval from the
Hertfordshire Research Ethics Committee (Number 07/
Q0204/68) and conducted in accordance with the 1964
Declaration of Helsinki and its later amendments.
RNA extraction
RNA from muscle tissue was extracted using the mirVana
miRNA Isolation Kit (ThermoFisher Scientific). Frozen muscle
samples were placed into 600 μL Lysis/Binding buffer and ho-
mogenized using a Dispomix Homogenizer (Miltenyi Biotech)
until all visible clumps were dispersed. The isolation proce-
dure was then performed according to the manufacturer’s in-
structions using the total RNA isolation protocol. RNA was
eluted in a volume of nuclease free water necessary to give
a concentration >25 ng/μL (40–100 μL). Quantity and quality
of total RNA was measured by Nanodrop (ThermoFisher
Scientific), Qubit 2.0 Fluorometer (ThermoFisher Scientific),
and Bioanalyzer (Agilent Technologies). All RNA had a RIN
of >8.0. Total RNA was stored at 80°C.
RNAseq
RNAseq was carried out as previously described.21 Briefly,
250 ng of total RNA was employed as starting material for
library preparation. Sequencing libraries were prepared using
the TruSeq Stranded Total RNA HT kit with the Ribo-Zero Gold
module (Illumina), followed by 13 cycles of PCR amplification
with the KAPA HiFi HotStart ReadyMix (Kapa BioSystems).
Libraries were quantified with Picogreen (Life Technologies),
and size pattern was controlled with the DNA High Sensitivity
Reagent kit on a LabChip GX (Perkin Elmer). Libraries were
then pooled at an equimolar ratio and clustered at a concen-
tration of 7 pM on paired-end sequencing flow cells (Illumina).
Sequencing was performed for 2 × 101 cycles on a HiSeq 2500
(Illumina) with v3 chemistry. The generated data were
demultiplexed using Casava. Reads were aligned to the human
genome (hs_GRCh38.p2) using TopHat,28 and the number of
reads mapped within genes was quantified by HTSeq29
(Version HTSeq-0.6.1p1, mode union, strand reverse, quality
alignment greater than 10). This procedure resulted in a
sequencing depth of 51–110 million reads per sample, out of
which 38–84 million were uniquely mapped. Data are publicly
available from GEO under Accession Numbers GSE111006,
GSE111010, and GSE111016 and integrated in the series
GSE111017.
Bioinformatic analysis
Differentially expressed genes with respect to ALMi were de-
termined using the DESeq2 package30 (v1.18.1) in R (v3.2.1).
Briefly, data were normalized using the relative log expres-
sion normalization method implemented in DESeq2. Indepen-
dent filtering was carried out as default by removing genes
with low expression. P-values were corrected for multiple
testing using the Benjamini–Hochberg method with genes
with a false discovery rate (FDR) < 0.2 classed as differen-
tially expressed.
Quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was carried out using a
LightCycler 480 Real-Time PCR System (Roche, UK); 500 ng to-
tal RNA was used as a template to prepare cDNA. RNA was
DNase treated (Sigma, UK) and reverse transcribed to cDNA
with the miScript II Reverse Transcription system (Qiagen).
cDNA was amplified with commercial real-time qRT-PCR
primers (Qiagen Quantitect, UK) using QuantiFast SYBR Green
Mastermix (Qiagen) according to the manufacturer’s recom-
mendations. The reaction was performed in a total volume
of 10 μL. Samples were measured in duplicate, and all techni-
cal replicates had a standard deviation (SD) < 1. Results were
analysed using the comparative CT (2ΔΔCT) method. House-
keeping genes were identified by GeNorm analysis (Primer
Design, UK). Ct values for mRNA analysis were normalized
to two endogenously expressed housekeeping genes (PPIA
and CYC1). Ct values for miRNA analysis were normalized to
four endogenously expressed small RNAs (RNU6, SNORD61,
SNORD68, and SNORD96A). For H19 expression, cDNA was
amplified using custom designed primers (Primer Design)
using the Taqman Gene Expression Master Mix
(ThermoFisher Scientific) according to the manufacturer’s
recommendations. List of primers used are shown in Table
S1, and melt curves in Figure S2.
Quantitative DNA methylation analysis
Genomic DNA was extracted from frozen muscle tissue
by classical proteinase K digestion and phenol:chloroform
extraction; 500 ng DNA was bisulfite converted using the
EZ DNA Methylation Gold Kit (Zymo Research, Ivrine,
CA) per the manufacturer’s protocol. PCR primers
specific for bisulfite-converted DNA were designed
using EpiDesigner (Agena). Each reverse primer contained
a T7-promoter tag for in vitro transcription (50-cagtaat
acgactcactatagggagaaggct-30), while the forward primer
had a 10mer tag to balance melting temperatures
(50-aggaagagag-30). The list of primers used are shown in
Table S1. Quantitative DNA methylation analysis was carried
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out using the Sequenom MassARRAY Compact System
(Agena). Bisulfite-converted DNA was amplified (Qiagen
HotStar Taq Polymerase), and Shrimp Alkaline Phosphatase
treated (Agena). Heat inactivation and simultaneous in vitro
transcription/uracil-cleavage reaction was subsequently car-
ried out. Products were desalted and spotted on a 384-pad
SpectroCHIP (Agena) using a MassARRAY nanodispender
(Samsung). Spectra were acquired using a MassArray
MALDI-TOF MS, and peak detection and quantitative CpG
methylation carried out using the EpiTyper software v1.0
(Agena).
Myoblast cultures
Biopsies were collected into 30 mL PBS and processed within
1 h of biopsy and digested with 2 mg/mL Collagenase Type 1A
in DMEM for 20 min at 37°C. The resulting suspension was
spun at 2200 g for 10 min and resuspended in 12 mL PBS.
Any remaining cell clumps were disassociated with a pipette
prior to being filtered through a 100 μm cell strainer. This cell
suspension was centrifuged and resuspended in prewarmed
proliferation media [DMEM containing 20% FBS, 10% horse
serum, 1% chick embryo extract (CEE), and 1% penicillin/
streptomycin]. To remove any contaminating fibroblasts, the
cell suspension was added to a non-matrigel coated 10 cm cell
culture dish and incubated at 37°C for 3 h. The cell suspension
was then transferred onto a new matrigel-coated plate (10%
matrigel in DMEM) and incubated at 37°C for 2 days. Media
were then changed daily. Cell populations were trypsinized
when they were 80% confluent. In order to differentiate myo-
blast cultures into myotubes, myoblasts were plated and
grown to confluence with subsequent substitution of prolifer-
ation media with differentiation media (DMEM containing 2%
horse serum and 1% penicillin/streptomycin). Cells were
shown to be of myogenic origin by staining with CD56.31
Transfection of siRNAs and mature microRNAs
Myotube cultures were transfected with siRNAs or miRNA
mimics at Passage 3; 10 pmol siRNA against H19 (Ambion)
and 10 pmol miR-675-3p/5p miRNA mimics (Ambion) were
transfected using the Lipofectamine RNAiMAX Transfection
Reagent (Life Technologies) following the manufacturer’s
protocol. Briefly, myoblasts were grown to confluence in pro-
liferation media, cells were washed, and media changed to
differentiation media (Day 0). Lipofectamine:siRNA/miRNA
complexes were added to the cells at Day 1 for 72 h. After
72 h, media were changed for fresh differentiation
media and cells allowed to differentiate for a further 2 days.
At Day 5, myotubes were harvested and frozen at 80°C
untilRNA/protein extraction. RNA from transfected myo-
blasts/myotubes was extracted using Tri reagent (Sigma)
following the manufacturer’s instructions. Quantity and qual-
ity of total RNA was measured by Nanodrop (ThermoFisher
Scientific). Total RNA was stored at 80°C until further use.
Western blotting
Muscle tissue was homogenized using a handheld
bio-vortexor homogenizer. Protein lysates from muscle tissue
were prepared in extraction buffer containing 50 mM Tris
(pH 7.5), 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 0.5% Triton
X-100 with 1 mM PMSF, and 0.25% leupeptin. Total protein
lysate concentrations were determined using a Pierce BCA
Colorimetric Protein Quantitation Assay (Thermo Scientific,
UK) and absorbance at 560 nm measured on the GloMax
Plate Reader (Promega). Due to the limited amount of muscle
tissue available, protein lysate from nine HSS muscle samples
were analysed; these were the only samples with sufficient
material remaining after RNA extraction. Twenty micrograms
of protein lysate was added to an equal volume of loading
buffer [125 mM Tris (pH 6.8), 200 mM DTT, 4% SDS, 20% glyc-
erol, and 0.2% bromophenol blue]. Denatured protein lysate
was resolved by 10% SDS PAGE. Protein transfer was per-
formed in buffer containing 25 mM Tris, 192 mM glycine,
20% (v/v) methanol, and 0.1% (w/v) SDS. The membrane
was blocked with 5% (w/v) dried skimmed milk powder
(Marvel, UK) in 1× TBS containing 0.05% (v/v) Tween-20.
Membrane sections were incubated overnight at 4°C with pri-
mary antibody diluted in blocking buffer followed by incuba-
tion with horseradish peroxidase-conjugated secondary
antibody. Primary antibodies used were anti-SMAD5
(1:1000, 9517S, CST), anti-SMAD1 (1:1000, ab33902, Abcam),
and anti-beta actin (1:1000, ab8224, Abcam). For SMAD1,
two bands were consistently visible with the anti-SMAD1 an-
tibody, the larger molecular weight band however was effi-
ciently competed out using a SMAD1 peptide (ab66722,
Abcam, Figure S3), and only the larger molecular weight band
was quantified. Secondary antibodies used were goat anti-
rabbit IgG H&L (HRP) (1:1000, ab6721, Abcam) and rabbit
anti-mouse IgG H&L (HRP) (1:1000, ab6728, Abcam). Protein
bands were detected using SuperSignal West Pico Plus
Chemiluminescent Substrate (Thermo Scientific). Blots were
imaged using a ChemicDoc XRS System (Biorad), with five im-
ages taken with exposures of 30, 60, 90, 120, and 150 s. The
image with an exposure of 90 s was used for quantification,
as this was within the linear range for quantification. Protein
band intensities were analysed using ImageJ software from
raw data images. Briefly, densitometry of the background
blot was subtracted from the band of interest, followed by
normalization to the loading control for each sample. β-Actin
was used as a loading control protein to allow normalization
of protein loading. Full images of the western blots are shown
in Figure S4.
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Immunohistochemistry
Immunohistochemistry was carried out on the muscle biop-
sies of men from the HSS as previously described in Patel
et al.32 Briefly, muscle tissue was fixed overnight at 20°C
before being embedded in glycol methacrylate resin. Serial
cross-sections at 7 μm were cut and stained for type II
fast-twitch myofibres using the monoclonal anti-myosin fast
antibody at a dilution of 1:6000 (clone MY-32; Sigma-Aldrich,
Dorset, UK). Stained sections were examined under a
photomicroscope (Zeiss Axioskop II, Carl Ziess Ltd, Welwyn
Garden City, UK) coupled to KS 400 image analysis software
(Image Associates, Bicester, UK). Sections were viewed at ×5
magnification and digitized to obtain tissue area, myofibre
number (type I, slow fibre vs. type II, fast fibre), and myofibre
cross-sectional areas (μm2). Slow and fast fibre proportions
were expressed as a percentage of total fibres. Muscle
morphology parameters were analysed in all samples by a
blinded observer.31
Statistical analysis
Regression analysis was used to analyse the expression of
genes with respect to the measures of muscle mass. The re-
gression analyses were carried out with age as a covariate
in the model for HSS participants, age and sex for the HSSe
cohort, and age, sex, and batch in the combined HSS and
HSSe data sets. All data were normally distributed, histo-
grams were checked to determine the normality of the distri-
bution of the residuals, and deviations in the QQ plot
(standardized residuals vs. theoretical quantiles) were exam-
ined. All regression statistics reported are from multivariate
regression models (Tables S2 and S3). Correlation analysis
was performed using Pearson correlation to compare the ex-
pression of the different genes. In transfection experiments
to determine the effect of H19 knockdown or ectopic expres-
sion of miR-675-3p/5p, a paired t-test was used.
Results
Participant characteristics
Summary of anthropometric and physical function of partici-
pants of HSS and HSSe is shown in Table 1. In HSS, all partic-
ipants were male, the mean age (SD) was 72.63 years (2.47),
height 1.74 m (0.07), weight 82.59 kg (13.06), body mass in-
dex (BMI) 27.33 kg/m2 (3.51), total lean body mass 56.02 kg
(6.66), appendicular lean mass 24.06 kg (3.23), total fat mass
22.32 kg (7.28), gait speed 1.11 m/s (0.19), and grip strength
37.56 kg (7.96). In HSSe, 29.3% (n = 38) of participants were
male. The mean (SD) age was 78.45 years (2.55), height
1.64 m (0.08), weight 72.36 kg (11.64), BMI 27.05 kg/m2
(3.88), total lean body mass 39.77 kg (6.98), appendicular
lean mass 16.65 kg (3.49), total fat mass 29.00 kg (8.24), gait
speed 0.96 m/s (0.20), and grip strength 25.17 kg (8.87).
Lower appendicular lean mass index is associated
with changes in the muscle transcriptome
To investigate changes in the muscle transcriptome that may
contribute to differences in muscle mass in older individuals,
total RNAseq was carried out on 40 muscle biopsies from the
vastus lateralis from male participants from the HSS and used
to identify genes whose expression was associated with
ALMi. The analysis of the RNAseq data showed that there
were 23 transcripts associated with ALMi (FDR < 0.25), of
which four had an FDR < 0.05 (Figure 1). There were H19
(FDR = 0.019) and Ankyrin Repeat Domain 20 Family Member
A1 (ANKRD20A1, FDR = 0.035), both negatively associated
with ALMI, and SH3 domain binding kinase family member
2 (SBK2, FDR = 1.34E-06) and paired-like homeodomain 1
(PITX1, FDR = 1.19E-04), both positively associated with ALMi
(Table 2).
Table 1 Cohort characteristics
HSS (n = 57) HSSe (n = 130) HSSe male (n = 38) HSSe female (n = 92)
Mean SD Mean SD Mean SD Mean SD
Male (%) 100% 29.2% NA NA
Age (years) 72.63 2.46 78.45 2.55 78.28 2.68 78.52 2.50
Height (m) 1.74 0.07 1.64 0.08 1.73 0.06 1.60 0.06
Weight (kg) 82.59 13.06 72.36 11.64 78.15 10.65 69.97 11.23
BMI (kg/m2) 27.33 3.51 27.05 3.88 26.17 3.24 27.42 44.08
Total lean body mass (kg) 56.02 6.66 39.77 6.98 48.77 4.92 36.56 4.28
Appendicular lean mass (kg) 24.06 3.23 16.65 3.49 21.06 2.49 15.04 2.17
Total fat mass (kg) 22.32 7.28 29.00 8.24 25.08 7.94 30.39 7.93
Gait speed (m/s) 1.11 0.19 0.96 0.20 1.00 0.22 0.94 0.18
Grip strength (kg) 37.56 7.96 25.17 8.87 35.74 6.67 20.76 5.17
BMI, body mass index; HSS, Hertfordshire Sarcopenia Study; HSSe, Hertfordshire Sarcopenia Study extension; NA, not applicable; SD, stan-
dard deviation.
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Higher H19 expression was associated with lower
appendicular lean mass index
In the RNAseq analysis, the transcript most significantly
down-regulated with respect to ALMi was H19, a long
non-coding RNA which is expressed primarily in muscle tissue
after birth, and which was previously reported by Lewis et al.,
to be inversely associated with low lean mass in chronic ob-
structive pulmonary disease (COPD) patients.33 To validate
the association between higher H19 expression and lower
ALMi, qRT-PCR was used. In 52 HSS samples (which included
34 samples with RNAseq data and 18 additional HSS samples
for which there was enough RNA for qRT-PCR analysis),
higher H19 expression was associated with lower ALMi
(r2 = 0.081, P = 0.056, Figure 2A). When restricting the analy-
sis to the samples for which there were both RNAseq and
qRT-PCR data (n = 34), the association was weakened slightly
(P = 0.128, Figure S5).
To replicate the findings in an independent set of individ-
uals and to examine whether the association was observed
in both men and women, H19 expression in relation to ALMi
was also analysed in 130 male and female individuals from
the HSSe cohort. Higher H19 expression was associated with
lower ALMi in the HSSe (r2 = 0.465, P< 0.001, Figure 2B) study
group. When stratifying by sex, we found that the association
between H19 and ALMi was significant in both men and
women (men P = 0.016, women P = 0.001), albeit weaker in
the men due to a smaller sample size. Moreover, when data
from both HSSe and HSS were combined, a significant inverse
association between H19 expression and ALMi was observed
(r2 = 0.650, P< 0.001, Figure 2C and Table S2). There was also
an inverse association between H19 expression and gait speed
(P = 0.040, Figure 2D) but no association with grip strength
(P = 0.615) in the combined HSS and HSSe study group.
H19 imprinting control region methylation
As H19 is a maternally imprinted gene, in which DNA
methylation plays an important regulatory role, we
assessed levels of DNA methylation at CpG sites within the
CTCF regulatory binding sites in the imprinting control region
(ICR) of H19 in the HSSe samples. The methylation of CpGs
within CTCF binding site 6 (CTCF6—CpG-2098: r = 0.231,
P = 0.043; CpGs-2103/-2105: r = 0.245, P = 0.038) and CTCF
binding site 3 (CTCF3) as well as three neighbouring CpGs
Table 2 List of differentially expressed genes with respect to
appendicular lean mass index (false discovery rate < 0.25)
ENSEMBL gene ID Estimate P-value FDR Gene symbol
Up-regulated
ENSG00000187550 0.19 5.53E-13 1.34E-08 SBK2
ENSG00000069011 0.26 9.81E-09 1.19E-04 PITX1
ENSG00000148218 0.12 2.42E-05 0.073 ALAD
ENSG00000105889 0.19 4.18E-05 0.096 STEAP1B
ENSG00000179715 0.2 4.54E-05 0.096 PCED1B
ENSG00000157330 0.09 1.28E-04 0.180 C1orf158
ENSG00000172461 0.15 1.44E-04 0.180 FUT9
ENSG00000117602 0.16 1.94E-04 0.214 RCAN3
ENSG00000211890 0.11 2.32E-04 0.244 IGHA2
Down-regulated
ENSG00000130600 0.21 3.18E-06 0.019 H19
ENSG00000260691 0.17 7.17E-06 0.035 ANKRD20A1
ENSG00000146477 0.2 2.11E-05 0.073 SLC22A3
ENSG00000223749 0.13 7.52E-05 0.130 MIR503HG
ENSG00000121577 0.14 1.26E-04 0.180 POPDC2
ENSG00000134107 0.17 1.49E-04 0.180 BHLHE40
ENSG00000182841 0.12 1.12E-04 0.180 RRP7BP
ENSG00000111664 0.18 1.66E-04 0.191 GNB3
FDR, Benjamini–Hochberg adjusted false discovery rate.
Figure 1 RNAseq differential expression with respect to appendicular lean mass index (ALMi) in muscle biopsies. (A) Volcano plot of the P-values ver-
sus log2 fold change. Genes with an FDR< 0.05 are shown in red, and those with an FDR between 0.05 and 0.25 shown in green. (B) Normalized count
of H19 from the RNAseq plotted against ALMi showing a negative association.
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(CpGs-4344/-4347/-4349/-4351: r = 0.211, P = 0.049; CpGs-
4288/-4290/-4294: r = 0.218, P = 0.042) showed a negative
correlation with H19 expression (Table 3). Methylation of
CpG-2098 and CpGs-2103/-2105 within the CTCF binding site
6 were also positively associated with ALMi (r2 = 0.341,
P = 0.036 and r2 = 0.373, P = 0.037, respectively) (Table 4).
Figure 2 Validation and replication of the expression of H19 in HSS and HSSe muscle tissue determined by qRT-PCR. (A) Association between H19
expression and ALMi in HSS study group. (B) Association between H19 expression and ALMi in HSSe. (C) Association between H19 expression and ALMi
in combined HSS and HSSe data sets. (D) Association between H19 expression and gait speed in combined HSS and HSSe data sets. Green points are
HSSe samples while black points are HSS samples. Statistics are from a multivariate regression model with adjustment for age in HSS (A), age and sex in
HSSe (B), and age, sex, and batch in the combined HSS and HSSe data sets (C and D). Regression coefficients for all models can be found in Table S2.
Table 3 Correlation between CpG methylation and H19 expression
CpG Genomic coordinates (hg19) N Pearson r P-value 95% CI (lower, upper)
CTCF6
CpG-2098 Chr11:2021203+ 77 0.231 0.043* 0.430, 0.007
CpGs-2103/-2105 Chr11:2021208/10+ 72 0.245 0.038* 1.645, 0.049
CTCF3
CpGs-4344/-4347/-4349/-4351 Chr11:2023449/52/54/56 87 0.211 0.049* 2.412, 0.002
CpGs-4288/-4290/-4294 Chr11:2023393/95/99 87 0.218 0.042* 2.599, 0.047
95% CI, 95% confidence interval.
*P < 0.05.
Table 4 Association between the methylation at CTCF sites and appendicular lean mass index
CpG Genomic coordinates (hg19) N r2 P-value 95% CI (lower, upper)
CTCF6
CpG-2098 Chr11:2021203+ 80 0.341 0.036* 0.177, 4.965
CpGs-2103/-2105 Chr11:2021208/10+ 74 0.373 0.037* 0.141, 4.280
CTCF3
CpGs-4344/-4347/-4349/-4351 Chr11:2023449/52/54/56 93 0.307 0.831 4.231, 3.327
CpGs-4288/-4290/-4294 Chr11:2023393/95/99 93 0.299 0.506 5.344, 2.656
95% CI, 95% confidence interval.
*P < 0.05.
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Higher miR-675-3p/5p expression is associated
with lower appendicular lean mass index
Exon 1 of H19 encodes two conserved miRNAs, miR-675-3p
and miR-675-5p (Figure 3A). We sought to investigate
whether the expression of these miRNAs showed a similar as-
sociation with ALMi, as observed with H19. We found in the
combined HSS and HSSe data set that lower ALMi was associ-
ated with higher miR-675-5p (r2 = 0.629, P = 0.005, Figure 3B)
and miR-675-3p (r2 = 0.598, P = 0.089, Figure 3C) expression.
Both mir-675-5p and mir-675-3p showed a significant positive
correlation with H19 expression (r = 0.192, P = 0.017 and
r = 0.182, P = 0.028, respectively) (Figure 3D and 3E and Table
S2). There were however sex differences in the association
between ALMi and miR-675-3p (men P = 0.074, women
P = 0.42) and miR-675-5p (men P = 0.001, women P = 0.171).
miR-675-3p/5p expression is associated with
altered SMAD1 and SMAD5 RNA and protein
expression
SMAD1 and SMAD5 mRNAs have been reported to be direct
targets of miR-675-3p.34 We found in the combined HSS and
HSSe data set that higher miR-675-3p expression was associ-
ated with lower SMAD1 and SMAD5 mRNA expression
(r2 = 0.146, P = 0.003 and r2 = 0.396, P = 0.034, respectively).
miR-675-5p also showed an inverse association with SMAD1
(r2 = 0.140, P = 0.004) and SMAD5 mRNA levels (r2 = 0.391,
P = 0.090, Figure 4A–4D and Table S3). Higher expression of
both miR-675-3p and miR-675-5p was also associated with
lower SMAD1 (r2 = 0.792, P < 0.001 and r2 = 0.760,
P = 0.001, respectively) and SMAD5 (r2 = 0.584, P = 0.011
and r2 = 0.723, P = 0.001, respectively) protein levels
Figure 3 miR-675-3p/5p expression in skeletal muscle tissue. (A) Schematic of the H19 gene, showing the localization of miR-675 in exon 1 of the H19
gene. (B) Association between miR-675-5p expression and ALMi. (C) Association between miR-675-3p expression and ALMi. (D + E) Correlation be-
tween the expression of miR-675-5p (D) and miR-675-3p (E) with H19. Statistics are from multivariate regression models with adjustment for age
and sex (A + B) and Pearson correlation analysis (D + E). Melt curves for B + C are in Figure S2.
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(Figure 4E–4I). Moreover, SMAD1 protein levels showed a
positive association with ALMi (P = 0.048, r2 = 0.856), al-
though no association was observed between SMAD5 protein
levels and ALMi (P = 0.376) (Table S3).
SMAD1/5 expression was associated with a
reduction in type II muscle fibre size
As SMAD1/5 expression has been linked to hypertrophy, we
also examined the relationship between SMAD1 and 5 ex-
pression and fibre size in muscle biopsies from HSS. Lower
SMAD1 and 5 mRNA expression was associated with a
reduction in larger type II (fast) muscle fibres (Figure 5,
r2 = 0.184, P = 0.037 and r2 = 0.246, P = 0.032, respectively).
There was no association between SMAD1 or 5 RNA levels
and type I (slow) muscle fibre area (Table S3).
The H19/miR-675-3p/5p axis directly affects the
expression of SMAD1/5
To determine whether alterations in the H19/miR-675-3p/5p
axis can directly affect SMAD1/5 expression in human primary
muscle cells, we used a siRNA directed against H19 to knock
down the expression of H19 in myotubes, differentiated from
Figure 4 SMAD1/5 RNA and protein expression in skeletal muscle and association with miR-675-3p/5p expression. (A + B) Association between SMAD1
mRNA levels andmiR-675-3p (A) andmiR-675-5p (B) expression. (C + D) Association between SMAD5mRNA andmiR-675-3p (C) andmiR-675-5p (D) ex-
pression. (E) Representative western blot for SMAD1 and SMAD5 protein in skeletal muscle tissue, with β-actin as a loading control. Full blots are avail-
able in Figure S5. (F–I) Association between SMAD1 (F + G) and SMAD5 (H + I) protein levels and miR-675-3p (F + H) and miR-675-5p (G + I) expression.
Statistics are from multivariate regression models with adjustment for age and sex (Table S3). Melt curve for SMAD1/5 qRT-PCR are in Figure S2.
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human primary myoblasts isolated from the HSSe muscle
biopsies. Transfection of a siRNA against H19 significantly de-
creased H19mRNA expression (P = 0.005), with a correspond-
ing decrease in the expression of both miR-675-3p (P = 0.009)
and miR-675-5p (P = 0.050) (Figure 6A). H19 knockdown also
induced a significant increase in levels of SMAD1 and SMAD5
mRNA (P = 0.002 and P = 0.006, respectively). To test whether
H19 acts throughmiR-675-3p/5p, to directly affect the expres-
sion of SMAD1/5, we introduced miR-675-3p and miR-675-5p
mimics into the myotubes and found a significant decrease
in SMAD1 and SMAD5mRNA (P = 0.030 and P = 0.020, respec-
tively) levels (Figure 6B), suggesting direct targeting of
SMAD1/5 by miR-675-3p/5p. Consistent with this, rescuing
miR-675-3p/5p expression by ectopic expression of the
miRNAs following H19 siRNA knockdown also showed a de-
crease in SMAD1 and SMAD5 mRNA (P = 0.008 and
P = 0.032, respectively) (Figure 6C).
Discussion
In this study, we report novel changes in the muscle tran-
scriptome associated with low muscle mass in older individ-
uals. We show that lower ALMi is associated with higher
expression of the long non-coding RNA H19 and its miRNA ef-
fectors miR-675-3p and miR-675-5p, and lower expression of
the anti-differentiation SMAD transcription factors, SMAD1
and SMAD5, which are direct targets of the microRNA, mir-
675-3p. There was an inverse correlation between H19 ex-
pression and DNA methylation within the H19 ICR, suggesting
that epigenetic processes may initiate or maintain the
differences observed in H19 expression associated with
changes in ALMi. Furthermore, we show that lower SMAD1
and 5 mRNA expression was associated with a reduction in
larger type II (fast) muscle fibres, suggesting that dysregula-
tion of the H19/miR-675/SMAD pathway may block the ana-
bolic signals associated with SMAD1/5 expression,
contributing and/or marking the loss of muscle mass in old
age.
Regulation of muscle mass requires the interplay of multi-
ple different genes and pathways.35 The top transcript
up-regulated in muscle tissue from individuals with high ALMi
was SBK2, a serine/threonine-protein kinase, while the top
transcript down-regulated in muscle samples from individuals
with high ALMi was H19, a long non-coding RNA of 2.4 kb in
length. Lewis et al. have previously reported that H19 was
up-regulated in COPD patients with low fat-free mass index
(FFMi) and low muscle strength.33 Our data would also sug-
gest that higher H19 expression is associated with loss of
muscle mass in old age and may have the potential to act
as a biomarker of muscle mass in the general population,
rather than being specifically related to muscle wasting in
COPD patients.
H19 has been reported to be highly expressed in embry-
onic tissues but down-regulated after birth in all tissues ex-
cept skeletal muscle,36 where it plays a pivotal role in
muscle differentiation. H19 expression is up-regulated during
the differentiation of mouse C2C12 cells, and during mouse
and human primary skeletal muscle satellite cell
differentiation.34,37,38 Moreover, knockdown of H19 expres-
sion in C2C12 cells or human skeletal muscle cells leads to a
decrease of myogenesis with a significant reduction in the ex-
pression of myogenic markers such as myogenin and MHC.34
Figure 5 Role of H19-miR-675-SMAD1/5 axis in skeletal muscle hypertrophy. (A) A serial cross section showing differential fibre staining. Darkly stained
fibres represent type II fast fibres. Bar represents 200 μM. (B) Association between SMAD1 RNA expression and type II (fast) fibre area (μm2). (C) As-
sociation between SMAD5 RNA expression and type II (fast) fibre area (μm2).
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As H19 enhances muscle cell differentiation, the increase in
H19 expression observed in this study associated with low
ALMi may indicate activation of regeneration and repair path-
ways in skeletal muscle from individuals with low muscle
mass.34
Exon 1 of H19 encodes two conserved microRNAs, miR-
675-3p and miR-675-5p, and H19 derived miR-675 has been
reported to play a major role in mediating the effects of
H19 on muscle cell differentiation. Dey et al.34 showed that
ectopic expression of either miR-675-3p or miR-675-5p res-
cued the reduction in muscle cell differentiation induced by
H19 knockdown in C2C12 cells and mouse and human satel-
lite cells, suggesting that miR-675-3p and miR-675-5p are ma-
jor contributors to the pro-differentiation function of H19.
miR-675-3p and miR-675-5p may influence muscle differenti-
ation by repressing the bone morphogenetic protein (BMP)
pathway by targeting the SMAD transcription factors, SMAD1
and SMAD5, which are direct targets of miR-675-3p, and the
cell division control protein 6 (CDC6), which is essential for
the initiation of DNA replication, and a direct target of miR-
675-5p. Interestingly co-knockdown of SMAD1, SMAD5, and
CDC6 in H19 siRNA transfected C2C12 cells was sufficient to
overcome the decrease in differentiation,33 suggesting that
these are important targets for the differentiation function
of H19. We have shown that there was a positive association
between H19 expression and miR-675-3p and miR-675-5p ex-
pression in muscle biopsies and that higher expression levels
of both H19 andmiR-675-3p and miR-675-5p were associated
with lower muscle mass. In muscle tissue, there was also a
negative association between miR-675-3p RNA expression
with levels of SMAD1 and 5 mRNA and protein levels, sug-
gesting that dysregulation of H19/miR-675/SMAD1/5 path-
way may be linked to loss of muscle mass in older
individuals. Furthermore, knockdown of H19 in primary hu-
man myotubes resulted in increased SMAD1/5 RNA levels,
while rescuing miR-675-3p/5p expression by ectopic expres-
sion of the miRNAs following H19 siRNA knockdown led to
a decrease in SMAD1 and SMAD5 mRNA levels, consistent
with SMAD1 and 5 being direct targets of miR-675-3p and
suggesting that miRNA regulation of SMAD1/5 expression
may be an important regulatory mechanism in human muscle
cells.
Studies in animal models have shown that SMAD1 and 5
positively regulate skeletal muscle mass by promoting
muscle growth and preventing muscle wasting.39,40
Over-expression of BMP7 or the BMP receptor ALK3 in
Figure 6 Effect of siRNA-mediated H19 knockdown and miR-675-3p/5p ectopic expression on SMAD1/5 levels in human primary myotubes. RNA ex-
pression levels of H19,miR-675-3p,miR-675-5p, SMAD1, and SMAD5 RNA (left to right) are shown in primary myotube cells following treatment with a
scrambled siRNA (-ve) and H19 siRNA (A), miR-675-3p/5p mimics (B), and H19 siRNA and miR-675-3p/5p mimics (rescue) (C). Data are shown as
mean ± SEM. **P < 0.01, *P < 0.05. All statistical analysis was paired-samples t-test (two-tailed), n = 9 per group.
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skeletal muscle in mice leads to increased SMAD1/5/8 phos-
phorylation, increased muscle hypertrophy, and increased
muscle fibre size, muscle mass, and force. Consistent with
this, here, we found that lower SMAD1 and 5 mRNA levels
were associated with smaller type II fast-twitch muscle fi-
bres. Muscle ageing has been associated with a reduction
in type II fibres type,41,42 which has been suggested to result
from denervation of type II muscle fibres with collateral
re-innervation of type I muscle fibres.42 These results sug-
gest that SMAD1/5, first shown to be important for main-
taining muscle mass in animal studies, may also play a role
in the loss of muscle mass in humans in old age. Further
studies however will be required to determine whether
SMAD1/5 and/or the H19/miR-675 pathway play a causal
role in the loss of muscle mass in old age.
The expression of H19 has been shown to be regulated
by imprinting, where the H19 gene is expressed from the
maternal allele and expression from the paternal allele is si-
lenced by DNA methylation. The H19 gene has an ICR up-
stream from its transcription start site.43 CTCF binding
sites in the ICR play key roles in the maintenance of
allele-specific expression of the gene. Interestingly, de-
creased H19 expression was associated with an increase
in methylation at two key CTCF sites, CTCF6 and CTCF3.
The CpGs within the CTCF 6, CpGs-2103/-2105 and CpG-
2098, the CpGs most strongly associated with H19 expres-
sion, were also positively associated with ALMi, suggesting
that epigenetic mechanisms may play a role in initiating
and/or maintaining the change in H19 expression associ-
ated with lower ALMi and contribute to the loss of muscle
mass in older individuals.
H19 expression was not associated with grip strength,
which EWGSOP2 has recently proposed to be the primary pa-
rameter of sarcopenia diagnosis in clinical practice, prior to
assessing muscle mass2 through imaging techniques. Interest-
ingly, our discovery of a robust association of high H19/mir-
675 with low muscle mass suggests that these non-coding
RNAs could be used as biomarkers as an alternative approach
to assess muscle mass. Non-coding RNAs especially miRNAs
have been showed to be present at significant levels in extra-
cellular bodily fluids, including blood serum and plasma.
Exosomes or microvesicle encapsulated miRNAs are released
from many cell types, including muscle,44–46 and are thought
to play a key role in communication between cells. Interest-
ingly, recent studies have showed that specific muscle miRNAs
have been detected in serum associated with the progression
of muscle wasting in myotonic dystrophy type 1.47 Further
work will be needed to determine whethermiR-675 is detect-
able in serum and associated with loss of muscle mass and has
potential as a biomarker of muscle quantity.
There are a number of limitations to this study. Firstly,
we carried out the RNAseq analysis on male participants
only; however, we did replicate the association observed
between H19 and ALMi using qRT-PCR in an independent
group of both men and women from the HSSe cohort, sug-
gesting that the association between the H19 and ALMi is
observed in both sexes. Lewis et al. also reported that
higher expression of miR-675 and its host gene H19 were
associated with lower FFMi in COPD patients although they
found no association between miR-675 expression and
FFMi in a subset of muscle samples from participants from
the HSS.33 However, there were a number of differences
between these studies. Here, we examined the relationship
between miR-675-3p and miR-675-5p with ALMi, rather
than FFMi. We also examined the expression of the two
miRNAs generated from H19, miR-675-3p, and miR-675-5p
in independent assays, rather than using a combined assay,
and we were able to assess expression in a larger number
of participants. Moreover, we observed associations be-
tween H19, its effector miRNAs, and the mRNA targets of
miR-675, supporting the robustness of our current findings
and suggesting that this axis is altered with respect to low
muscle mass index. The second limitation to this study was
that there was a relatively high number of participants who
were overweight or obese in both the HSS and HSSe co-
horts. However, adjusting for total body fat or % fat mass
did not alter the list of transcripts significantly associated
with ALMi. Thirdly, although we found changes in DNA
methylation across CTCF sites within the H19 ICR associated
with both H19 expression and low muscle mass, the
changes observed in DNA methylation were small. DNA
methylation within a cell is binary; thus, the small differ-
ences in DNA methylation observed in the muscle samples
are likely to represent changes in the number of cells ex-
pressing H19 and/or differences in the cellular composition
of the tissue with respect to ALMi, both of which may ulti-
mately affect muscle function. Fourthly, because of the in-
vasive nature of human muscle biopsies in volunteer
participants, we only had low quantities of protein remain-
ing for western blot analysis and further replication of the
western blot analysis to assess SMAD protein expression
is required. However, we did see a down-regulation of
SMAD1/5 mRNA expression in relation to miR-675 expres-
sion, suggesting that miR-675 may regulate SMAD1/5
mRNA levels. Finally, we were only able to assess the effect
of H19 knockdown in primary human myotube cultures on
SMAD1/5 mRNA levels rather than at the protein level due
to insufficient material. miRNAs repress gene expression by
binding to their target mRNAs and either induce mRNA
degradation or inhibit the translation of the mRNA. Here,
we observed an increase in SMAD1/5 mRNA levels upon
H19 knockdown, which was reversed by the addition of
miR-675 mimics, but whether SMAD1/5 translation was
also affected requires further investigation. However, these
experiments do suggest that H19/miR-675/SMAD1/5 axis
identified by Dey et al. in mouse C2C12 cells also operates
in human myoblasts and may play a role in loss of muscle
mass in older individuals.34
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Conclusions
This study is the first to show that changes in H19 expression
in human skeletal muscle are associated with skeletal muscle
mass in older people. Moreover, the increase in H19 expres-
sion associated with low ALMi was accompanied by an in-
crease in miR-675-3p/5p expression and a decrease in
SMAD1/5 mRNA, targets of miR-675-3p, suggesting that dys-
regulation of this pathway in individuals with lower ALMi may
mark the activation of muscle repair/regeneration pathways
and/or block anabolic signals associated with SMAD1/5 ex-
pression. The finding that the H19/miR-675/SMAD1/5 path-
way may play a role in the loss of muscle mass in older
individuals may allow the development of new intervention
strategies to slow the age-related loss of muscle mass in later
life using antagomirs,48 designed to repress the miRNAs im-
plicated in this pathway.
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shire Sarcopenia Study extension (HSSe) is an independent
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males and 92 females had sufficient RNA for qRT-PCR. The
data was combined (HSS + HSSe) to improve overall power.
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To investigate the role of H19, 9 samples from HSSe (selected
to represent a range of H19 expression) were used for H19
knockdown and miR-675-3p/5p overexpression analysis.
Figure S2. Melt curves for HSS + HSSe qRT-PCR.
Figure S3. Specificity of anti-SMAD1 (ab33902) antibody. (A)
SMAD1 staining in 2 myoblast samples and 2 positive controls
(untreated HeLa cell lysates and UV-treated HeLa lysates).
Two bands are present in the myoblast samples, but only
the top band is present in the HeLa controls lysates. (B)
SMAD1 staining in 2 myoblast samples and 4 muscle tissue
samples, showing the two bands as seen in the first image.
(C) SMAD1 staining in the presence of a SMAD1 peptide
(ab66722). The presence of the peptide competes binding
of the SMAD1 antibody to the top band, however the bottom
band is still present in all samples. The top band is used for
quantification of SMAD1 protein levels in all subsequent ex-
periments.
Figure S4. Full western blots images from figure 4. Lanes are
labelled with their respective sample ID numbers. Lanes
with † indicate a lane failing western blot QC due to gel/filter
issues.
Figure S5. Association of H19 in muscle biopsies from HSS
which had both RNAseq and qRT-PCR data. Statistics are from
a multivariate regression model with adjustment for age.
Conflict of interest
E.M. and J.N.F. are full-time employees of the Société des
Produits Nestlé SA. K.M.G. and H.P.P. have received reim-
bursement for speaking at conferences sponsored by compa-
nies selling nutritional products and are part of an academic
consortium that has received research funding from Abbott
Nutrition, Nestec, and Danone. E.A., E.S.G., P.T., S.J.B., A.S.,
C.M., T.F., C.C., K.M.G., and K.A.L. are part of academic re-
search programmes that have received research funding from
Abbott Nutrition, Nestec, and Danone. The other authors
confirm that they have no conflicts of interest.
References
1. Clynes MA, Edwards MH, Buehring B,
Dennison EM, Binkley N, Cooper C.
Definitions of sarcopenia: associations with
previous falls and fracture in a
population sample. Calcif Tissue Int
2015;97:445–452.
2. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y,
Bruyere O, Cederholm T, et al. Sarcopenia:
revised European consensus on definition
and diagnosis. Age Ageing 2019;48:601.
3. McCarthy JJ, Esser KA. Anabolic and cata-
bolic pathways regulating skeletal muscle
mass. Curr Opin Clin Nutr Metab Care
2010;13:230–235.
4. Cuthbertson D, Smith K, Babraj J, Leese G,
Waddell T, Atherton P, et al. Anabolic sig-
naling deficits underlie amino acid resis-
tance of wasting, aging muscle. FASEB J
2005;19:422–424.
5. Fry CS, Drummond MJ, Glynn EL, Dickinson
JM, Gundermann DM, Timmerman KL,
et al. Aging impairs contraction-induced
human skeletal muscle mTORC1 signaling
and protein synthesis. Skelet Muscle
2011;1:11.
6. Delbono O. Neural control of aging skeletal
muscle. Aging Cell 2003;2:21–29.
7. Shea KL, Xiang W, LaPorta VS, Licht JD,
Keller C, Basson MA, et al. Sprouty1
regulates reversible quiescence of a self-
renewing adult muscle stem cell pool
during regeneration. Cell Stem Cell
2010;6:117–129.
8. Bigot A, Duddy WJ, Ouandaogo ZG,
Negroni E, Mariot V, Ghimbovschi S, et al.
Age-associated methylation suppresses
SPRY1, leading to a failure of re-quiescence
and loss of the reserve stem cell pool in el-
derly muscle. Cell Rep 2015;13:1172–1182.
9. Hepple RT. Mitochondrial involvement and
impact in aging skeletal muscle. Front
Aging Neurosci 2014;6:211.
10. Short KR, Bigelow ML, Kahl J, Singh R,
Coenen-Schimke J, Raghavakaimal S, et al.
Decline in skeletal muscle mitochondrial
function with aging in humans. Proc Natl
Acad Sci U S A 2005;102:5618–5623.
11. Barton ER, Morris L, Musaro A, Rosenthal
N, Sweeney HL. Muscle-specific expression
of insulin-like growth factor I counters
muscle decline in mdx mice. J Cell Biol
2002;157:137–148.
12. Chambon C, Duteil D, Vignaud A, Ferry A,
Messaddeq N, Malivindi R, et al. Myocytic
androgen receptor controls the strength
but not the mass of limb muscles. Proc Natl
Acad Sci U S A 2010;107:14327–14332.
13. Hardman SE, Hall DE, Cabrera AJ, Hancock
CR, Thomson DM. The effects of age and
muscle contraction on AMPK activity and
heterotrimer composition. Exp Gerontol
2014;55:120–128.
14. Langley B, Thomas M, Bishop A, Sharma M,
Gilmour S, Kambadur R. Myostatin inhibits
myoblast differentiation by down-
regulating MyoD expression. J Biol Chem
2002;277:49831–49840.
15. Conboy IM, Conboy MJ, Smythe GM,
Rando TA. Notch-mediated restoration of
regenerative potential to aged muscle. Sci-
ence 2003;302:1575–1577.
16. Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ,
Keller C, et al. Increased Wnt signaling dur-
ing aging alters muscle stem cell fate and in-
creases fibrosis. Science 2007;317:807–810.
17. Liao ZY, Chen JL, Xiao MH, Sun Y, Zhao YX,
Pu D, et al. The effect of exercise, resvera-
trol or their combination on sarcopenia in
aged rats via regulation of AMPK/Sirt1
pathway. Exp Gerontol 2017;98:177–183.
18. Alway SE, Martyn JK, Ouyang J, Chaudhrai
A, Murlasits ZS. Id2 expression during apo-
ptosis and satellite cell activation in
unloaded and loaded quail skeletal mus-
cles. Am J Physiol Regul Integr Comp Phys-
iol 2003;284:R540–R549.
19. Zahn JM, Sonu R, Vogel H, Crane E, Mazan-
Mamczarz K, Rabkin R, et al. Transcrip-
tional profiling of aging in human muscle
reveals a common aging signature. PLoS
Genet 2006;2:e115.
20. de Magalhaes JP, Curado J, Church GM.
Meta-analysis of age-related gene expres-
sion profiles identifies common signatures
of aging. Bioinformatics 2009;25:875–881.
21. Migliavacca E, Tay SKH, Patel HP, Sonntag
T, Civiletto G, McFarlane C, et al.
Mitochondrial oxidative capacity and
NAD
+
biosynthesis are reduced in human
sarcopenia across ethnicities. Nat Commun
2019;10:5808.
22. Zillikens M, Demissie C, Hsu S, Yerges-
Armstrong YH, Chou LM, Stolk WC, et al.
Large meta-analysis of genome-wide asso-
ciation studies identifies five loci for lean
body mass. Nat Commun 2017;8:80.
23. Matteini AM, Tanaka T, Karasik D, Atzmon
G, Chou WC, Eicher JD, et al. GWAS analy-
sis of handgrip and lower body strength
in older adults in the CHARGE consortium.
Aging Cell 2016;15:792–800.
24. Syddall HE, Aihie Sayer A, Dennison EM,
Martin HJ, Barker DJ, Cooper C. Cohort pro-
file: the Hertfordshire cohort study. Int J
Epidemiol 2005;34:1234–1242.
25. Patel HP, Syddall HE, Martin HJ, Stewart CE,
Cooper C, Sayer AA. Hertfordshire
220 E. Antoun et al.
JCSM Rapid Communications 2021; 4: 207–221
DOI: 10.1002/rco2.44
sarcopenia study: design and methods.
BMC Geriatr 2010;10:43.
26. Patel HP, Al-Shanti N, Davies LC, Barton SJ,
Grounds MD, Tellam RL, et al. Lean mass,
muscle strength and gene expression in
community dwelling older men:
findings from the Hertfordshire Sarcopenia
Study (HSS). Calcif Tissue Int
2014;95:308–316.
27. Patel H, Syddall HE, Martin HJ, Cooper C,
Stewart C, Sayer AA. The feasibility and ac-
ceptability of muscle biopsy in epidemio-
logical studies: findings from the
Hertfordshire Sarcopenia Study (HSS). J
Nutr Health Aging 2011;15:10–15.
28. Trapnell C, Pachter L, Salzberg SL. TopHat:
discovering splice junctions with RNA-Seq.
Bioinformatics 2009;25:1105–1111.
29. Anders S, Pyl PT, Huber W. HTSeq—a
Python framework to work with
high-throughput sequencing data. Bioinfor-
matics 2015;31:166–169.
30. Love MI, Huber W, Anders S. Moderated
estimation of fold change and dispersion
for RNA-seq data with DESeq2. Genome
Biol 2014;15:550.
31. Cashman NR, Covault J, Wollman RL,
Sanes JR. Neural cell adhesion molecule
in normal, denervated, and myopathic
human muscle. Ann Neurol 1987;21:
481–489.
32. Patel HP, White MC, Westbury L, Syddall
HE, Stephens PJ, Clough GF, et al. Skeletal
muscle morphology in sarcopenia defined
using the EWGSOP criteria: findings from
the Hertfordshire Sarcopenia Study (HSS).
BMC Geriatr 2015;15:171.
33. Lewis A, Lee JY, Donaldson AV, Natanek SA,
Vaidyanathan S, Man WD, et al. Increased
expression of H19/miR-675 is associated
with a low fat-free mass index in patients
with COPD. J Cachexia Sarcopenia Muscle
2016;7:330–344.
34. Dey BK, Pfeifer K, Dutta A. The H19 long
noncoding RNA gives rise to microRNAs
miR-675-3p and miR-675-5p to promote
skeletal muscle differentiation and regen-
eration. Genes Dev 2014;28:491–501.
35. Egerman MA, Glass DJ. Signaling pathways
controlling skeletal muscle mass. Crit Rev
Biochem Mol Biol 2014;49:59–68.
36. Gabory A, Jammes H, Dandolo L. The H19
locus: role of an imprinted non-coding
RNA in growth and development.
Bioessays 2010;32:473–480.
37. Milligan L, Antoine E, Bisbal C, Weber M,
Brunel C, Forne T, et al. H19 gene expres-
sion is up-regulated exclusively by stabiliza-
tion of the RNA during muscle cell
differentiation. Oncogene 2000;19:
5810–5816.
38. Xu X, Ji S, Li W, Yi B, Li H, Zhang H, et al.
LncRNA H19 promotes the differentiation
of bovine skeletal muscle satellite cells by
suppressing Sirt1/FoxO1. Cell Mol Biol Lett
2017;22:10.
39. Winbanks CE, Chen JL, Qian H, Liu Y,
Bernardo BC, Beyer C, et al. The bone mor-
phogenetic protein axis is a positive regula-
tor of skeletal muscle mass. J Cell Biol
2013;203:345–357.
40. Sartori R, Sandri M. Bone and morphoge-
netic protein signalling and muscle
mass. Curr Opin Clin Nutr Metab Care
2015;18:215–220.
41. Brunner F, Schmid A, Sheikhzadeh A,
Nordin M, Yoon J, Frankel V. Effects of ag-
ing on Type II muscle fibers: a systematic
review of the literature. J Aging Phys Act
2007;15:336–348.
42. Deschenes MR. Effects of aging on muscle
fibre type and size. Sports Med
2004;34:809–824.
43. Szabo PE, Tang SH, Silva FJ, Tsark WM,
Mann JR. Role of CTCF binding sites in the
Igf2/H19 imprinting control region. Mol
Cell Biol 2004;24:4791–4800.
44. Guescini M, Guidolin D, Vallorani L, Casadei
L, Gioacchini AM, Tibollo P, et al.
C2C12 myoblasts release micro-vesicles
containing mtDNA and proteins involved
in signal transduction. Exp Cell Res
2010;316:1977–1984.
45. Le Bihan MC, Bigot A, Jensen SS, Dennis JL,
Rogowska-Wrzesinska A, Laine J, et al. In-
depth analysis of the secretome identifies
three major independent secretory path-
ways in differentiating human myoblasts.
J Proteomics 2012;77:344–356.
46. Forterre A, Jalabert A, Chikh K, Pesenti S,
Euthine V, Granjon A, et al. Myotube-
derived exosomal miRNAs downregulate
Sirtuin1 in myoblasts during muscle cell
differentiation. Cell Cycle 2014;13:78–89.
47. Koutsoulidou A, Photiades M, Kyriakides
TC, Georgiou K, Prokopi M, Kapnisis K,
et al. Identification of exosomal
muscle-specific miRNAs in serum of myo-
tonic dystrophy patients relating to muscle
disease progress. Hum Mol Genet
2017;26:3285–3302.
48. Krutzfeldt J, Rajewsky N, Braich R, Rajeev
KG, Tuschl T, Manoharan M, et al. Silencing
of microRNAs in vivo with ‘antagomirs’.
Nature 2005;438:685–689.
49. von Haehling S, Morley JE, Coats AJS, Anker
SD. Ethical guidelines for publishing in the
Journal of Cachexia, Sarcopenia and Mus-
cle: update 2019. J Cachexia Sarcopenia
Muscle 2019;10:1143–1145.
Altered H19/miR-675 expression in skeletal muscle 221
JCSM Rapid Communications 2021; 4: 207–221
DOI: 10.1002/rco2.44
